MA44645B1 - Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2 - Google Patents
Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2Info
- Publication number
- MA44645B1 MA44645B1 MA44645A MA44645A MA44645B1 MA 44645 B1 MA44645 B1 MA 44645B1 MA 44645 A MA44645 A MA 44645A MA 44645 A MA44645 A MA 44645A MA 44645 B1 MA44645 B1 MA 44645B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- antibody
- bcl
- combined treatment
- mdm2
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title abstract 4
- 229940123711 Bcl2 inhibitor Drugs 0.000 title abstract 4
- 229940083338 MDM2 inhibitor Drugs 0.000 title abstract 4
- 239000012819 MDM2-Inhibitor Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960003347 obinutuzumab Drugs 0.000 abstract 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical group C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 abstract 1
- 229960001183 venetoclax Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne un traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2 pour le traitement du cancer, en particulier un traitement combiné des cancers exprimant cd20 avec un anticorps anti-cd20 de type i ou d'un anticorps b-lyl humanisé afucosylé et un inhibiteur de bcl-2 et un inhibiteur de mdm2. De préférence, l'anticorps anti-cd20 est l'obinutuzumab. De préférence, l'inhibiteur de bcl-2 est le vénétoclax. De préférence, l'inhibiteur de mdm2 est rg7388.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15169199 | 2015-05-26 | ||
| EP16725104.0A EP3302549B1 (fr) | 2015-05-26 | 2016-05-23 | Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2 |
| PCT/EP2016/061517 WO2016188935A1 (fr) | 2015-05-26 | 2016-05-23 | Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44645B1 true MA44645B1 (fr) | 2019-09-30 |
Family
ID=53264535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44645A MA44645B1 (fr) | 2015-05-26 | 2016-05-23 | Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20160347852A1 (fr) |
| EP (1) | EP3302549B1 (fr) |
| JP (1) | JP6612362B2 (fr) |
| KR (1) | KR102043803B1 (fr) |
| CN (1) | CN107847600B (fr) |
| AR (1) | AR104735A1 (fr) |
| AU (1) | AU2016267564B2 (fr) |
| BR (1) | BR112017023517A2 (fr) |
| CA (1) | CA2984706A1 (fr) |
| CL (1) | CL2017002983A1 (fr) |
| CR (1) | CR20170529A (fr) |
| DK (1) | DK3302549T3 (fr) |
| ES (1) | ES2744624T3 (fr) |
| HK (1) | HK1252855A1 (fr) |
| HR (1) | HRP20191585T1 (fr) |
| HU (1) | HUE044853T2 (fr) |
| IL (1) | IL255353B (fr) |
| LT (1) | LT3302549T (fr) |
| MA (1) | MA44645B1 (fr) |
| MX (1) | MX2017014977A (fr) |
| MY (1) | MY188849A (fr) |
| NZ (1) | NZ736727A (fr) |
| PE (1) | PE20180454A1 (fr) |
| PL (1) | PL3302549T3 (fr) |
| PT (1) | PT3302549T (fr) |
| RS (1) | RS59204B1 (fr) |
| RU (1) | RU2727196C2 (fr) |
| SI (1) | SI3302549T1 (fr) |
| UA (1) | UA124617C2 (fr) |
| WO (1) | WO2016188935A1 (fr) |
| ZA (1) | ZA201707357B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014039855A1 (fr) | 2012-09-07 | 2014-03-13 | Genentech, Inc. | Thérapie combinée d'un anticorps anti-cd20 de type ii et d'un inhibiteur sélectif de bcl-2 |
| US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3054632A1 (fr) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libere a l'aide d'un dispositif ingerable |
| EP3713607A1 (fr) * | 2017-11-22 | 2020-09-30 | Nordic Nanovector ASA | Utilisation de radio-immunoconjugués en combinaison avec d'autres médicaments en tant que traitement contre le lnh |
| MX2020007392A (es) | 2018-01-10 | 2020-10-14 | Recurium Ip Holdings Llc | Compuestos de benzamida. |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (fr) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme |
| CN110772640B (zh) * | 2018-07-31 | 2023-02-03 | 苏州亚盛药业有限公司 | Bcl-2抑制剂与利妥昔单抗和/或苯达莫司汀或与CHOP联合的协同抗肿瘤作用 |
| WO2020024834A1 (fr) | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Produit de combinaison d'un inhibiteur de bcl-2 et d'un agent chimiothérapeutique et utilisation associée dans la prévention et/ou le traitement de maladies |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| EP3870261B1 (fr) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Dispositif ingestible pour la livraison d'un agent thérapeutique au système gastro-intestinal |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| CN103261229A (zh) * | 2010-12-16 | 2013-08-21 | 罗切格利卡特公司 | 无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法 |
-
2016
- 2016-05-23 UA UAA201712737A patent/UA124617C2/uk unknown
- 2016-05-23 DK DK16725104.0T patent/DK3302549T3/da active
- 2016-05-23 ES ES16725104T patent/ES2744624T3/es active Active
- 2016-05-23 HU HUE16725104 patent/HUE044853T2/hu unknown
- 2016-05-23 BR BR112017023517-0A patent/BR112017023517A2/pt active Search and Examination
- 2016-05-23 AU AU2016267564A patent/AU2016267564B2/en not_active Ceased
- 2016-05-23 PE PE2017002462A patent/PE20180454A1/es unknown
- 2016-05-23 EP EP16725104.0A patent/EP3302549B1/fr active Active
- 2016-05-23 RU RU2017145649A patent/RU2727196C2/ru active
- 2016-05-23 PL PL16725104T patent/PL3302549T3/pl unknown
- 2016-05-23 RS RSP20191139 patent/RS59204B1/sr unknown
- 2016-05-23 WO PCT/EP2016/061517 patent/WO2016188935A1/fr active Application Filing
- 2016-05-23 MX MX2017014977A patent/MX2017014977A/es unknown
- 2016-05-23 CA CA2984706A patent/CA2984706A1/fr active Pending
- 2016-05-23 KR KR1020177036968A patent/KR102043803B1/ko active IP Right Grant
- 2016-05-23 CN CN201680043763.1A patent/CN107847600B/zh not_active Expired - Fee Related
- 2016-05-23 LT LTEP16725104.0T patent/LT3302549T/lt unknown
- 2016-05-23 MY MYPI2017704447A patent/MY188849A/en unknown
- 2016-05-23 PT PT16725104T patent/PT3302549T/pt unknown
- 2016-05-23 MA MA44645A patent/MA44645B1/fr unknown
- 2016-05-23 JP JP2017561265A patent/JP6612362B2/ja active Active
- 2016-05-23 NZ NZ736727A patent/NZ736727A/en not_active IP Right Cessation
- 2016-05-23 CR CR20170529A patent/CR20170529A/es unknown
- 2016-05-23 SI SI201630376T patent/SI3302549T1/sl unknown
- 2016-05-24 AR ARP160101500A patent/AR104735A1/es unknown
- 2016-05-26 US US15/166,149 patent/US20160347852A1/en not_active Abandoned
-
2017
- 2017-10-30 ZA ZA2017/07357A patent/ZA201707357B/en unknown
- 2017-10-31 IL IL255353A patent/IL255353B/en unknown
- 2017-11-24 CL CL2017002983A patent/CL2017002983A1/es unknown
-
2018
- 2018-09-21 HK HK18112186.9A patent/HK1252855A1/zh unknown
-
2019
- 2019-09-03 HR HRP20191585 patent/HRP20191585T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44645B1 (fr) | Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2 | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| MA33469B1 (fr) | Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| MA47313A (fr) | Formulations sous-cutanées d'anticorps her2 | |
| MA53356B1 (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
| MA41013B1 (fr) | Compositions comprenant des souches bactériennes | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| EA201992546A1 (ru) | Средства на основе антител к cd33 | |
| EA201891040A1 (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| MA40576B1 (fr) | Anticorps et immunoconjugués anti-her2 | |
| PE20161217A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
| MA39094A1 (fr) | Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
| MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
| MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| EA201790334A1 (ru) | Конъюгаты анти-cdh6 антитела с лекарственным средством | |
| MA33470B1 (fr) | Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone | |
| FR3021970B1 (fr) | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs | |
| MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| EA201992316A1 (ru) | Композиции и способы для диагностики рака предстательной железы | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
| EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников | |
| MA45831B1 (fr) | Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation | |
| TR201908138T4 (tr) | Bir anti-her2 antikoru ilaç konjügatı ve bir bcl-2 inhibitörü ile kombinasyon terapisi. |